Mounjaro vs Zepbound: same drug, different label
Updated July 31, 2026
Short answer
Mounjaro and Zepbound are both tirzepatide from Eli Lilly at identical 2.5–15 mg weekly doses. The only meaningful differences are the approved indication — type 2 diabetes for Mounjaro, chronic weight management and obstructive sleep apnea in obesity for Zepbound — and how insurance covers each. Protein, electrolyte, magnesium, fiber, and vitamin needs are the same on both.
Mounjaro vs Zepbound side by side
| Attribute | Mounjaro | Zepbound |
|---|---|---|
| Active ingredient | Tirzepatide | Tirzepatide |
| Maker | Eli Lilly | Eli Lilly |
| Approved for | Type 2 diabetes | Weight management, OSA in obesity |
| Dose range | 2.5–15 mg weekly | 2.5–15 mg weekly |
| Mechanism | Dual GIP/GLP-1 | Dual GIP/GLP-1 |
| Protein target | 0.8–1.0 g/lb goal weight | 0.8–1.0 g/lb goal weight |
| Supplement stack | Identical | Identical |
What changes for nutrition and supplements
- Nothing about the molecule differs, so no supplement should be swapped when switching brands.
- Weight-management users on Zepbound often lose faster, which raises the priority of protein and resistance training.
- Both brands suppress appetite most in the 24–72 hours after injection; liquid protein and electrolytes cover that window.
The verdict
Choose based on your diagnosis and insurance coverage with your prescriber.
Keep the same nutrition plan on either brand: protein first, electrolytes daily, magnesium at night, fiber for regularity.
Frequently asked
Keep reading
Educational information only, not medical advice. Choosing between medications is a decision for you and your prescriber. Brand names are the trademarks of their respective owners.